Recently, the UK’s National Institute for Health and Care Excellence (NICE) has recommended the country’s first long-acting injectable treatment for HIV-1 infection in adults.
Cabotegravir with Rilpivirine is recommended as an option for adults with HIV-1 infection.
Currently treatment for HIV involves lifelong antiretroviral tablets that need to be taken every day, which keep viral loads to levels at which the infection cannot be detected and transmitted between individuals. Clinical trial results show that Cabotegravir with Rilpivirine is as effective as oral antiretrovirals at keeping the viral load low.
